Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 50

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 50
---
 information to you by referring you to those documents; and |

| • |     | information we file with the SEC will automatically update and supersede information contained in this 
 prospectus.                                                                                            |

We incorporate by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement and (ii) on or after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn:

38

Notwithstanding the foregoing, information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K,including the related exhibits under Item 9.01, is not incorporated by reference in this prospectus. You may request a copy of any of these filings, at no cost, by request directed to us at the following address or telephone number: TuHURA Biosciences, Inc. 10500 University Center Drive, Suite 110 Tampa, Florida 33612 (813) 875-6600 Attention: Chief Financial Officer You should not assume that the information in this prospectus or any prospectus supplement, as well as the information we file or previously filed with the SEC that we incorporate by reference in this prospectus or any prospectus supplement, is accurate as of any date other than the respective date of such documents. Our business, financial condition, results of operations and prospects may have changed since that date. 39

The information in this preliminary prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED NOVEMBER 3, 2025

PROSPECTUS SUPPLEMENT

(To Prospectus Dated , 2025)

$50,000,000

Common Stock

We have entered into an At the Market Offering Agreement (the “Sales Agreement”), dated November 3, 2025, with H.C.
Wainwright & Co., LLC (the “Sales Agent